| Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. | |
| | |
MedLine Citation:
|
PMID: 20335789 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
A retrospective cohort study was conducted to determine if there is an association between short-acting intramuscular (SAIM) antipsychotics used for acute agitation and length of stay (LOS). Patients with a diagnosis of schizophrenia or schizoaffective disorder who were dispensed at least one dose of a SAIM antipsychotic were divided into groups based on the initial SAIM antipsychotic received once admitted to a psychiatric unit. Electronic records were used to gather demographic information, LOS, and number of injections received during an admission. Cost was calculated from the number of injections received. One-hundred and thirty-six patients were enrolled. When comparing the haloperidol group to the second generation antipsychotic group, there was no statistically significant difference, in LOS 16.98 ± 9.56 days versus 17.59 ± 11.52 days (P = 0.75), respectively. There was a statistically significant difference in both cost and number of injections between groups, favoring the haloperidol group. Ziprasidone was associated with a shorter LOS compared with olanzapine, 13.57 and 19.10 days, respectively (P = 0.026). Patient characteristics should be evaluated when determining an agent for acute agitation. However, because literature indicates second generation SAIM antipsychotics are only noninferior to haloperidol; other factors should also be evaluated; including impact on LOS and impact on hospital resources. This study indicates use of a second generation SAIM antipsychotic for acute agitation is more costly, requires more injections, and was not associated with a shorter length of stay when compared with SAIM haloperidol. |
| | |
Authors:
|
Jonathan G Leung; Amanda M Benedetti; Lawrence A Frazee; Nancy Myers |
Related Documents
:
|
2704509 - The application of a computer data base system to the generation of hospital discharge ... 15239219 - Ceftriaxone is twice as cost-effective as standard therapy in biliary tract infection. 17559739 - The cost of treating ribavirin-induced anemia in hepatitis c: the impact of using recom... 19298219 - Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis ... 15323579 - Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leuk... 19916729 - Retrospective study of total healthcare costs associated with chronic nonvalvular atria... 15875929 - Predictors of relapse among pulmonary tuberculosis patients treated in a dots programme... 15531349 - Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival ana... 22208179 - Delayed high-quality cpr does not improve outcomes. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of therapeutics Volume: 18 ISSN: 1536-3686 ISO Abbreviation: Am J Ther Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-07-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9441347 Medline TA: Am J Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 300-4 Citation Subset: IM |
Affiliation:
|
1Virginia Commonwealth University Health System, Richmond, VA; 2Cancer Pain Program, Akron General Medical Center Department of Pharmacy, Akron, OH; 3Department of Internal Medicine, Akron General Medical Center, Akron, OH; and 4Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chemotherapy versus surgery in primary B-cell lymphoma masquerading as klatskin tumor-a diagnostic a...
Next Document: Drug development in oncology: a regulatory perspective.